Mylan N.V. (MYL) Stock Rating Reaffirmed by Cowen and Company
Mylan N.V. (NASDAQ:MYL)‘s stock had its “market perform” rating reiterated by stock analysts at Cowen and Company in a report released on Thursday. They presently have a $36.00 price target on the stock, up from their prior price target of $30.00. Cowen and Company’s target price points to a potential downside of 4.76% from the company’s current price.
A number of other equities analysts also recently weighed in on the stock. Zacks Investment Research raised shares of Mylan N.V. from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Royal Bank Of Canada set a $41.00 price target on shares of Mylan N.V. and gave the stock a “hold” rating in a research note on Sunday, July 16th. Citigroup Inc. raised shares of Mylan N.V. from a “neutral” rating to a “buy” rating and increased their price target for the stock from $36.00 to $42.00 in a research note on Wednesday, August 16th. BidaskClub raised shares of Mylan N.V. from a “strong sell” rating to a “sell” rating in a research note on Friday, June 16th. Finally, Cantor Fitzgerald initiated coverage on shares of Mylan N.V. in a research note on Friday, June 16th. They set a “neutral” rating and a $41.00 price target on the stock. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Mylan N.V. presently has an average rating of “Buy” and a consensus price target of $42.34.
Shares of Mylan N.V. (NASDAQ MYL) opened at 37.80 on Thursday. The stock’s 50 day moving average is $31.65 and its 200 day moving average is $36.47. Mylan N.V. has a 52-week low of $29.39 and a 52-week high of $45.87. The stock has a market cap of $20.27 billion, a price-to-earnings ratio of 30.56 and a beta of 1.30.
Mylan N.V. (NASDAQ:MYL) last posted its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.18 by ($0.08). The company had revenue of $2.96 billion for the quarter, compared to analysts’ expectations of $3 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The business’s revenue for the quarter was up 15.7% on a year-over-year basis. During the same period in the prior year, the business earned $1.16 EPS. On average, equities analysts expect that Mylan N.V. will post $4.52 earnings per share for the current fiscal year.
WARNING: “Mylan N.V. (MYL) Stock Rating Reaffirmed by Cowen and Company” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/05/mylan-n-v-myl-stock-rating-reaffirmed-by-cowen-and-company.html.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Global X Management Co. LLC grew its holdings in Mylan N.V. by 91.6% during the 1st quarter. Global X Management Co. LLC now owns 3,015 shares of the company’s stock valued at $118,000 after purchasing an additional 1,441 shares in the last quarter. TLP Group LLC acquired a new stake in Mylan N.V. during the 1st quarter valued at $200,000. Doliver Capital Advisors LP acquired a new stake in Mylan N.V. during the 2nd quarter valued at $201,000. Eagle Global Advisors LLC acquired a new stake in Mylan N.V. during the 2nd quarter valued at $205,000. Finally, Sheaff Brock Investment Advisors LLC acquired a new stake in Mylan N.V. during the 2nd quarter valued at $210,000. 71.97% of the stock is owned by institutional investors and hedge funds.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.